4 results
Using a single formulation of PfPEBS LSP administered at two different doses, one of 5*g and the other one of 30*g, both adjuvanted with aluminium hydroxide, in two immunizations at 28 days interval, to evaluate a) the safety and immunogenicity (…
1.) First, we hypothesize that a reduction of myocardial damage explained by lower levels of myocardial damage markers (e.g. troponin I, CK-MB) by sevoflurane may be related to a reduction of inflammatory mediators (i.e. TNF-α, CD11b/CD18 cells, and…
Safety and efficacy objectives:The objective is to compare the safety and efficacy of masitinib at 6 of 7.5 mg/kg/day to imatinib at 400 or 600 mg, in patients with gastro-intestinal stromal tumour in first line medical treatment.
The objective is to compare the efficacy and safety of masitinib 12 mg/kg/day to sinutinib 50 mg/day